Abstract:Abstract Background: Glycolysis, a multi-step enzymatic reaction, is considered to be the root of cancer development and progression. The aim of this study is to figure out the glycolytic enzyme, phosphoglycerate kinase 1 (PGK1) whether participate in the progression of acute myeloid leukemia (AML) and its possible mechanisms. Methods: Four datasets (GSE106096, GSE75086, GSE107968 and GSE106748) containing 30 leukemic blast cell samples of AML at diagnosis, 17 leukemic blast cell samples of AML relapse and 3 bone marrow CD34+ cell samples of healthy donors were downloaded from Gene Expression Omnibus (GEO) database and PGK1 was screened out as a potential survival biomarker in AML. Then we did a series of clinical sample verifications and gene set enrichment analysis (GSEA) focusing on PGK1. We further knocked down expression of PGK1 in myelogenous leukemia cell lines and explored its potential effects. Results: PGK1 expression was up-regulated among AML at diagnosis versus healthy control, AML relapse versus AML at diagnosis and AML relapse versus healthy control datasets. Through a serial of bioinformatic analyses (differentially expressed genes [DEGs] selection, function and pathway enrichments and protein-protein interaction [PPI] network establishment), PGK1 was identified as the most meaningful gene in AML progression. Furthermore, the generally high expression of PGK1 was confirmed in AML samples comparing with healthy controls in our single center and the high-expression PGK1 was associated with a comparatively low complete remission (CR) rate, a significantly high 5-year cumulative incidence of relapse (CIR), a poor 5-year event-free survival (EFS) rate, and a poor 5-year overall survival (OS) rate. The GSEA revealed that high-expression PGK1 in AML was associated with many pathways including cytosolic DNA sensing, pentose phosphate, base excision repair and DNA replication. In vitro, the transfected U937 and K562 cells with PGK1 knock-down showed decreased cell viability and increased apoptotic rate. PGK1 inhibition could greatly decrease the half maximal inhibitory concentrations (IC50) of cytarabine (Ara-C) and daunorubicin (DNR) in U937 and K562 cell lines.Conclusions: High-expression PGK1 was associated with poor prognosis in AML. PGK1 may serve to predict the AML progression and provide a novel therapeutic target for AML.

Expression and Significance of PKM1 in Acute Myeloid Leukaemia

Expression and Clinical Significance of Phospholipase D1 in De Novo Acute Myeloid Leukemia

Expression and Clinical Significance of ID1 Gene in Acute Myeloid Leukemia

Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia

[Expression Level of SET Gene in Acute Myeloid Leukemia and Its Clinical Significance].

PKM2 is a Potential Prognostic Biomarker and Related to Immune Infiltration in Lung Cancer

High expression of PKM2 synergizes with PD-L1 in tumor cells and immune cells to predict worse survival in human lung adenocarcinoma

High Expression of Midkine (MK) Indicates Poor Prognosis in Childhood Acute Lymphoblastic Leukemia.

PGK1, a Promising Biomarker and Therapeutic Target for Patients with Acute Myeloid Leukemia Who Are Susceptible to Disease Relapse

Overexpression of PDK2 and PDK3 Reflects Poor Prognosis in Acute Myeloid Leukemia

Expression and clinical significance of NPM1 gene in patients with acute myeloid leukemia

Clinical Significance of Decreased GPX1 Expression in Patients with Acute Myeloid Leukaemia (Non-M3).

High Expression of Pyruvate Kinase M2 is Associated with Chemosensitivity to Epirubicin and 5-Fluorouracil in Breast Cancer.

Prognostic Significance of Metabolic Enzyme Pyruvate Kinase M2 in Breast Cancer A Meta-Analysis

Overexpression of Pyruvate Kinase M2 in Tumor Tissues is Associated with Poor Prognosis in Patients with Hepatocellular Carcinoma

PKM2 Upregulation Promotes Malignancy and Indicates Poor Prognosis for Intrahepatic Cholangiocarcinoma.

Clinicopathological and prognostic significance of PKM2 protein expression in cirrhotic hepatocellular carcinoma and non-cirrhotic hepatocellular carcinoma

Clinical Significance of DNMT1 and EZH2 Gene Expression in Patients with Acute Leukemia

The Prognostic Value of PKM2 and Its Correlation with Tumour Cell PD-L1 in Lung Adenocarcinoma

Expression and Significance of PKR Mrna in Chronic Myelogenous Leukemia

Prognostic Significance of the PANK Family Expression in Acute Myeloid Leukemia.